BioSpace News Archive

Celanese Announces Commercial Launch of Glaukos’ iDose ® TR (Travoprost Intracameral Implant) Using Celanese’s VitalDose ® Ethylene Vinyl Acetate (EVA).

Planet Labs PBC (NYSE:PL), a leading provider of daily data and insights about Earth, today announced that it plans to release its fiscal fourth quarter and full year 2024 financial results for the year that ended January 31, 2024, after market close on Thursday, March 28, 2024.

Devonian Health Group Inc. announced today that the board of directors of the Corporation (the “ Board ”) has appointed pharmaceutical industry veteran Ms. Kathryn J. Gregory to the Board, effective February 28, 2024.

Cosmos Health Inc. announced the successful acquisition of the distribution network owned by Pharmatrade S.A., an established pharmaceutical wholesale company operating in Greece.

Applied Biomics, Inc., a leading Proteomics service provider, launches a new product line offering Anti-HCP Antibodies with well over 95% coverage.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial results for the period ending December 31, 2023.

ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN) today announced it has received a favorable patentability opinion from the European Patent Office (EPO) acting as the International Examiner on a polymorph patent application for farudodstat which, if granted in the national stages, will extend effective patent protection for farudodstat until at least 2043.

JAMP Pharma Group, a leading company in the Canadian pharmaceutical industry for over 35 years, announces subject to Superior Court approval and the fulfillment of customary closing conditions, the acquisition of the assets of Pharmalab’s manufacturing facility in Lévis, which ceased operations in August 2023.

Avidity Biosciences, Inc. announced that it has agreed to sell 15,224,773 shares of its common stock at a price of $16.50 per share and pre-funded warrants to purchase 9,030,851 shares of its common stock at a price per pre-funded warrant of $16.4990 to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement.

Enveric Biosciences is pleased to announce that it has signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds.